Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

Study:

A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM

Rationale:

n/a

Purpose:

The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields (termed TTFields).

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Recurrent Glioblastoma Multiforme Device: NovoTTF-100A Phase 3

Verified by NovoCure Ltd. April, 2012

Sponsored by: NovoCure Ltd.
Information provided by: NovoCure Ltd.
ClinicalTrials.gov identifier: NCT00379470

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio
United States

Phillip Gutin, MD., Principal Investigator
Roger Stupp, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site